Bedford Metals Corp News - BFM

Immatics Announces First Quarter 2024 Financial Results and Business Update

Immatics Announces First Quarter 2024 Financial Results and Business Update Company Provides Clinical Data Update from Ongoing Phase 1...

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Immatics Announces Full Year 2023 Financial Results and Corporate Update Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in...

Immatics Announces Pricing of $175 Million Public Offering

Immatics Announces Pricing of $175 Million Public Offering Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ:...

Immatics Announces Proposed Public Offering

Immatics Announces Proposed Public Offering Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX...

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Immatics Announces Third Quarter 2023 Financial Results and Business Update ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12...

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial...

Immatics veröffentlicht Daten aus laufender Phase-1-Zelltherapie-Studie ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME

Immatics veröffentlicht Daten aus laufender Phase-1-Zelltherapie-Studie ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Bedford Metals Corp (BFM)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

BFM News

Immatics Announces First Quarter 2024 Financial Results and Business Update

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Immatics Announces Pricing of $175 Million Public Offering

Immatics Announces Proposed Public Offering

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Immatics veröffentlicht Ergebnisse des dritten Quartals 2022 sowie ein Update zur Geschäftsentwicklung

Immatics gibt garantiertes öffentliches Zeichnungsangebot von Stammaktien im Wert von $110 Millionen bekannt

Immatics veröffentlicht Daten aus laufender Phase-1-Zelltherapie-Studie ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME

BFM Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Bedford Metals Corp (BFM) News

Bedford Metals Corp (BFM)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

BFM News

Immatics Announces First Quarter 2024 Financial Results and Business Update

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Immatics Announces Pricing of $175 Million Public Offering

Immatics Announces Proposed Public Offering

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Immatics veröffentlicht Ergebnisse des dritten Quartals 2022 sowie ein Update zur Geschäftsentwicklung

Immatics gibt garantiertes öffentliches Zeichnungsangebot von Stammaktien im Wert von $110 Millionen bekannt

Immatics veröffentlicht Daten aus laufender Phase-1-Zelltherapie-Studie ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME

BFM Discussion

Your Recent History